Background: Pseudomonas aeruginosa is the primary cause of infection with impaired defense mechanisms. P. aeruginosa commonly causes nosocomial infections and is the most common pathogen isolated from patients hospitalized for longer than 1 week. We examined the antimicrobial effect of multilayered carbon nanotubes on multi-drugresistant.
Introduction
Pseudomonas aeruginosa is a gram negative bacterium that is environmentally ubiquitous. It can also be an opportunist pathogen. [1] Multi-drug-resistant (MDR) P. aeruginosa can be difficult to eradicate using a variety of therapies. [2] The consequence can be severe diseases or worsening of existing conditions, including cystic fibrosis and burns.
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Hadis Mousavi et al P. aeruginosa typically causes infections in immunocompromised individuals, but can be active in immunocompetent individuals. The persistence of P. aeruginosa in a variety of habitats hinders treatment, [3] as does its resistance to carbapenem. [4, 5] Carbapenem antibiotic is often the antibiotic of last resort in severe and life threatening infections caused by MDR gram negative bacteria. Understanding the resistance to carbapenem is important. [6] As well, the efficacy of conventional antibiotics can be compromised as a result of their overuse and they can have side effects. Drugs that are more effective with fewer side effects are needed. [7] In seeking alternatives, the unique properties of nano-sized structures have attracted attention. [8] Nanoparticles with antimicrobial activity can more active, less toxic, and less expensive compared to the antibiotics that are currently used. In addition, nanoparticles administered in smaller doses can have a longer half-life in the body. Biological nanotechnology is one of the most promising fields of basic science and the new material being developed have potential value in medical biology. [9, 10] Carbon nanotubes (CNTs) are the first generation of nanoparticles, which have been commercially available for nearly two decades. [7] Nanoparticles conjugated with conventional antibiotics have many benefits, including minimizing the side effects of the antibiotics and facilitate the binding of antibiotics to the target microorganisms. [11] Nano-materials alone or conjugated with specific compounds, such as antibiotics, may have potential therapeutic value. [12] Conjugation of nanoparticles with antibiotics may produce a synergistic effect, which can permit lower doses of the antibiotics to be used, minimizing the side effects. [13] In this study, we investigated antimicrobial properties of multilayered CNTs for clinical isolates of MDR P. aeruginosa.
Materials and Methods

Clinical isolates
Twenty P. aeruginosa isolates were collected from blood, cerebrospinal fluid, urine, wound swabs, urethral swabs, and sputum from patients during treatment at Motahari hospital (Tehran, Iran) in a 3-month period. All isolates were characterized by biochemical assay. Pseudomonas aeruginosa (ATCC 27853) was used as the standard strain.
Screening of antibacterial activity by disk diffusion
The conventional method of agar diffusion was used to assess antibiotic susceptibility. A single colony of each isolate was inoculated into a test tube containing 2 ml LB broth (Oxoid, Basingstoke, UK) and incubated overnight. The culture of each isolate was 
Preparation of multilayered CNTs
CNT in powder form for MIC testing was purchased as single packs (US Research Co., USA). Specifications and characteristics are summarized in Tables 1 and 2 . Multi-walled CNTs ( MCNTs) were functionalized using 3H 2 SO 4 :2HNO 3 solution with 98% and 65% acid concentrations, respectively. The mixture of the acid solution and MWCNTs were kept at 140 ∘ C for 4 h, followed by dilution in distilled water for 6 h until the pH reached 7. The diluted solution was filtered through a 0.2 µm filter. The functionalized MWCNTs were dried in a 60 ∘ C oven for 24 h and characterized using thermogravimetric analysis (TGA) scanning electron microscopy(FEI Quanta 200 ESEM). Manufacturing Method Chemical vapor deposition 
Broth microdilution determination of MICs
Broth microdilution was used to determine the MIC of imipenem alone and in combination with SWCNTs. To reach an 8 µg/mL concentration, imipenem and functionalized SWCNTs (f-SWCNTs) was dissolved in dimethyl sulfoxide (DMSO) and distilled water, respectively. These solutions were serially diluted 11 times with Muller Hinton broth (Merck).
For detection of DMSO antibacterial activity, DMSO in Muller Hinton broth was serially diluted from 50% to 0.098%. Each isolate was added to duplicate wells to achieve final bacterial concentration of 5×10 5 colony forming units (CFU)/mL, except for the bacteriafree negative control. The enzyme-linked immunosorbent assay plates were incubated for 18 h at 35 ∘ C. The absorbance of each well was determined at 630 nm using a microplate reader (Awareness Technology Inc., Palm City, FL, USA). Muller Hinton broth was the blank. The lowest concentration with any visible growth was considered to be the MIC.
Evaluating synergistic effect of antibiotic and CNTs
After determining the MIC, the microdilution broth method was used to evaluate the efficacy of each antibacterial agent, including imipenem, and the MWCNTs prior to conjugation.
Results
As per the convention for the agar diffusion test, the results were interpreted based on the presence or absence of an inhibitory zone of growth. If the bacteria were susceptible to the antimicrobial agent, a zone of growth inhibition appeared around the disk. The absence of an inhibition zone demonstrated resistance to the particular antibiotic.
A representative scanning electron microscopy view of MWCNTs is shown in Figure   2 . Of the 20 clinical isolates of P. aeruginosa, 17 (85%) were resistant to one or more antibiotics (Table 3) . Resistance was highest to clindamycin followed by imipenem. Resistance was lowest for ofloxacin . 
Discussion
The present comparison of the antimicrobial effect of CNTs and imipenem, which is the antibiotic of last resort for MDR infections caused by gram negative bacteria including P. aeruginosa, was prompted by the increased resistance to imipenem and concomitant elevated risk of infection and mortality. The idea behind the study was that CNTs could be an alternate therapeutic option to conventional antibiotics, with effective antibacterial activity, fewer side effects, and reduced acquisition of antibacterial resistance. [15] The first data concerning the prowess of MWCNTs were provided a decade ago. The superior antibacterial efficacy and reduced cytotoxicity of MWCNTs compared to SWCNTs were reported. The superior performance against Escherichia coli was because of the size. [16] The present data demonstrates that this antibacterial efficacy extends to clinical isolates of P. aeruginosa. The isolates displayed the most pronounced resistance is to clindamycin (68%) followed by imipenem (59%), with the least resistance observed to in Spain, 13.4% in Russia, 12% in Canada, and 8.3% in Japan. [21, 22] The presently observed imipenem resistance rate in Iran is markedly higher (59%), which indicates a dangerous impact on public health.
Haifi et al. analyzed the efficacy of an imipenem-colistin conjugate as a therapeutic combination against Enterobacter-resistant to multiple antibiotics. The documented activity of colistin alone and in combination with imipenem against Enterobacter species indicated the therapeutic value of the combination for digestive system infections. [23] Similarly, the combination of imipenem and CNTs was synergistically active against MDR P. aeruginosa, indicating that it might be a substitute to carbapenem. Cemal et al. CNTs showed negligible toxicity; however, further studies of its biosafety are necessary before the strategy can be commercialized. [25] The present and prior findings support the conclusion that MWCNTs are very effective when used along with imipenem, with synergistic activity evident against clinical isolates of P. aeruginosa. The strategy may be a valuable replacement for conventional antibiotics in the treatment of P. aeruginosa infections.
